Author

N. Murthy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Organism:mouse· 2 Assay:CRISPR screen· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:multiome· 1

Frequent Co-Authors

A. Jozic· 1 shared A. Kerr· 1 shared A. Roberts· 1 shared A. W. Roberts· 1 shared B. W. Burgstone· 1 shared B. Xu· 1 shared B. Yin· 1 shared C. C. Ward· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. Jozic

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Synthesis of ionizable lipopolymers using split-Ugi reaction for pulmonary delivery of various size RNAs and gene editing

K. Y. Vlasova, A. Kerr, N. D. Pennock, A. Jozic, D. Sahel, M. Gautam, N. Murthy, A. Roberts, M. W. Ali, K. D. MacDonald, J. Walker, R. Luxenhofer, G. Sahay

The paper develops a method to deliver various RNA therapeutics, including mRNA and CRISPR-Cas9, to the lung using lipopolymer-lipid hybrid nanoparticles, showing improved efficacy and reduced toxicity.

bioRxiv · Jun 11, 2024Bioengineering

Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR-Cas9 RNP

K. Chen, H. Han, S. Zhao, B. Xu, B. Yin, M. Trinidad, B. W. Burgstone, N. Murthy, J. A. Doudna

This study demonstrates that lipid nanoparticle-delivered thermostable Cas9 RNPs achieve high-efficiency genome editing in mouse liver and lung tissues.

bioRxiv · Nov 15, 2023Bioengineering

Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2

S. B. Biering, E. Van Dis, E. Wehri, L. H. Yamashiro, X. Nguyenla, C. Dugast-Darzacq, T. G. Graham, J. R. Stroumza, G. R. Golovkine, A. W. Roberts, D. M. Fines, J. N. Spradlin, C. C. Ward, T. Bajaj, D. Dovala, , S. A. Stanley

This study screens FDA-approved compounds for antiviral activity against SARS-CoV-2 and identifies 13 effective compounds, including seven new candidates and one synergistic combination with remdesivir.

bioRxiv · Dec 30, 2020Microbiology